Skip to main content
Premium Trial:

Request an Annual Quote

Tranzyme Exclusively Licenses Trans-Lentiviral Vector Technology to Open Biosystems

NEW YORK, Nov. 14 (GenomeWeb News) - Open Biosystems has obtained an exclusive license to use Tranzyme Pharma's trans-lentiviral gene-expression technology, the company said today.


Under the agreement, Open Biosystems can develop and commercialize products based on the gene-expression technology. Open Biosystems will assume Tranzyme's Birmingham, Ala., operations and expand lentiviral-based product development and production.


Tranzyme will receive minimum annual payments and royalties on sales of products and services that depend on its technology, Open Biosystems said. The amount for the minimum payments was not disclosed.


Tranzyme's human-based trans-lentiviral gene expression technology can be used in neuroscience research, and Open Biosystems will provide proprietary research reagents and services based on lentiviral vectors.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.